Showing results (281-290 of 12,932) with videos related to
Sort By:
Pageof 1,294
Journal of the American College of Cardiology|September 10, 2016
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 AnalysisJan Steffel, Robert P Giugliano, Eugene Braunwald, et al.International Journal of Cardiology|May 21, 2023
Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trialAntonio Fagundes, Christian T Ruff, David A Morrow, et al.Circulation|July 4, 2018
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 TrialOphelia Q P Yin, Elliott M Antman, Eugene Braunwald, et al.JACC. Clinical Electrophysiology|April 26, 2023
Risks of Heart Failure, Stroke, and Bleeding in Atrial Fibrillation According to Heart Failure PhenotypesRiccardo M Inciardi, Robert P Giugliano, Jeong-Gun Park, et al.Circulation|December 28, 2018
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48David D Berg, Christian T Ruff, Petr Jarolim, et al.American Heart Journal|January 8, 1999
Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial InfarctionJ R Kizer, C P Cannon, C H McCabe, et al.American Heart Journal|November 8, 2002
Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administrationHoward A Cooper, James A de Lemos, David A Morrow, et al.Lancet (London, England)|November 13, 2020
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trialsBaris Gencer, Nicholas A Marston, KyungAh Im, et al.Journal of the American College of Cardiology|October 8, 2021
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-ITKazuma Oyama, Robert P Giugliano, Michael A Blazing, et al.Journal of the American College of Cardiology|October 2, 2002
Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromesNeal S Kleiman, Nasser Lakkis, Christopher P Cannon, et al.Pageof 1,294